PDCD1 and acute kidney injury: While most studies support that there is no difference in AKI risk with CTLA-4 and PD-1 inhibitor monotherapy (16–18, 22–26, 28, 29), PD-L1 inhibitors such as atezolizumab, durvalumab and avelumab may have a lower risk of AKI (<1%) (30).